載入中
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
前收盤價
US$15.53
+US$0.07 · +0.45%
盤中時間採用ET。市場資料可能有所延遲。
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
日內區間
目前US$15.53
52週區間
目前US$15.53
盤中時間採用ET。市場資料可能有所延遲。
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
日內區間
目前US$15.53
52週區間
目前US$15.53
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | — | 1894.3萬 USD |
| 銷貨成本 | — | 30.6萬 USD | — | — | — |
| 毛利 | — | −30.6萬 USD | — | — | 1894.3萬 USD |
| 研究與開發 | 1.87億 USD | 1.43億 USD | 1.48億 USD | 9194.8萬 USD | 5775.1萬 USD |
| 銷售、一般及管理費用 | 5424.6萬 USD | 5371萬 USD | 4249.3萬 USD | 4018.9萬 USD | 2914.6萬 USD |
| 營業費用 | 2.42億 USD | 1.97億 USD | 1.91億 USD | −1.45億 USD | 8689.7萬 USD |
| 利息收入 | 2221.2萬 USD | 2966萬 USD | 2162.7萬 USD | 661.1萬 USD | 47.7萬 USD |
| 折舊和攤銷 | 31.1萬 USD | 30.6萬 USD | 31萬 USD | 9.3萬 USD | 5.3萬 USD |
| 營業利益 | −2.42億 USD | −1.97億 USD | −1.91億 USD | 1.45億 USD | −6795.4萬 USD |
| 淨利 | −2.2億 USD | −1.67億 USD | −1.53億 USD | 1.11億 USD | −6557萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$34.75
上漲空間 123.76%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI4314.01萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM2468.24萬0.03%787.4億 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI1921.5萬0.19%98.74億 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF1373.86萬0.01%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO767.77萬0.04%180億 USD0.06%US$112.66+0.50%
iShares Biotechnology ETFIBB564.22萬0.05%108.2億 USD0.44%US$206.49+3.00%
Dimensional - US Small Cap ETFDFAS528.85萬0.02%338.69億 USD0.31%US$78.35+0.32%
Fidelity Enhanced Small Cap ETFFESM480.31萬0.07%64.1億 USD0.28%US$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASFidelity Enhanced Small Cap ETFFESMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
